RECENT ADVANCE IN BASIC SCIENCE
JAK-STAT signaling pathway: new therapeutic targets in inflammatory bowel diseases
Luca Scarallo, Monica Paci
1Struttura Complessa Gastroenterologia e Nutrizione, Ospedale Meyer, Firenze
A major innovation in the management of inflammatory bowel diseases (IBD) has been the development of small molecules. Compared to previously approved biologic agents, Janus Kinase (Jak) inhibitors have a short halflife, rapid onset of action and no immunogenicity. The aim of this narrative review is to summarizes the current data regarding the use, safety, and efficacy of Jak inhibitors in patients with IBD